REG - Futura Medical PLC - Futura Medical extends collaboration with Cooper

Futura MedicalAnnouncement

15/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240115:nRSO5668Za&default-theme=true

RNS Number : 5668Z  Futura Medical PLC  15 January 2024

 

15 January 2024

 Futura Medical plc

("Futura" or the "Company")

Futura Medical extends collaboration with Cooper Consumer Health

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical
company developing innovative sexual health products, today announces that it
has extended until January  2029 its exclusive licensing agreement with
Cooper Consumer Health ("Cooper"), a leading European independent self-care
organisation, for the rights to commercialise Eroxon®, the Company's topical,
gel-based Erectile Dysfunction ("ED") treatment, throughout the European
Economic Area, United Kingdom and Switzerland.

The extension builds on an initial agreement signed in May 2022 for the
exclusive rights to commercialise Eroxon in these territories for an initial
five-year period. The terms of the agreement are otherwise unchanged with
Futura remaining the Legal Manufacturer(1) and responsible for the supply of
Eroxon through its third-party contract manufacturers.  Futura looks forward
to continuing to grow its relationship with Cooper.

Eroxon has been approved as the first pan-European topical treatment for ED
available without prescription. Initial launches commenced in March 2023 in
the UK and Belgium, with further launches across Europe during 2024, including
the key markets of Italy, Spain, France and Germany.

James Barder, Chief Executive Officer of Futura Medical said: "The
award-winning launch of Eroxon was a key milestone in our partnership with
Cooper and the success of our collaboration makes this extension an easy
decision for both parties. We are committed to providing treatment to those
suffering from ED and as such we continue the commercial roll-out of Eroxon
across the world."

Bart Meermans, President of Cooper Consumer Health said: "Cooper's ambition is
to become a leading European consumer healthcare platform. Eroxon is an
exciting new innovation for the erectile dysfunction market and we look
forward to working closely with Futura with the continuing launches of Eroxon
across our markets."

(1) Legal manufacturer means the organisation responsible for the design,
manufacture, packaging and labelling of a device before it is placed on the
market under that organisation's own name, regardless of whether these
operations are carried out by that organisation or on its behalf by a third
party contract manufacturer.

 

ENDS

 

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Elena Bates

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative sexual health products based on its proprietary,
transdermal DermaSys® technology. Each DermaSys® formulation is separately
patented and specifically tailored for the selected indication and
application, as well as being optimised for clinical efficacy, safety,
administration and patient convenience. The products are developed for the
prescription and consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action and is
sold in Europe and the UK under the brand name Eroxon®. Futura has conducted
two Phase 3 studies using MED3000 in ED; the FM57 study which enabled Futura
to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US
marketing authorisation. Both studies demonstrated that MED3000 presents an
effective clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for an 'Over the
Counter' classification.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)

 

About Cooper Consumer Health Group

Cooper Consumer Health Group ("Cooper") is the largest independent selfcare
organization in Europe that is active in the OTC consumer healthcare market
with the development, manufacturing, selling and marketing of selfcare
products (e.g. medicines, medical devices, cosmetics, biocides and food
supplements) under its own or licensed brands.

The ambition of the group is to offer selfcare solutions to everyone based on
a European brands portfolio. Cooper has proven its capacity to integrate new
activities and  aggregate talents by capitalising on the strengths and the
structure of its group. www.cooperconsumerhealth.eu
(http://www.cooperconsumerhealth.eu)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBBGDBXGBDGSD